<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="176073">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803452</url>
  </required_header>
  <id_info>
    <org_study_id>lipidtearfilm</org_study_id>
    <secondary_id>NEI RO-1- EY017094-02</secondary_id>
    <nct_id>NCT00803452</nct_id>
  </id_info>
  <brief_title>Lipids of the Human Tear Film and Their Effect on Tear Stability</brief_title>
  <official_title>Lipids of the Human Tear Film and Their Effect on Tear Stability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, comparative clinical trial evaluates the effect of either oral
      doxycycline, oral essential fatty acid, or topical azithromycin to modify the secretions of
      the meibomian gland in subjects with meibomian gland dysfunction and/or dry eye disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with meibomian gland dysfunction undergo expression of the meibomian gland
      secretion prior to beginning treatment with either oral doxycycline, oral essential fatty
      acids, or topical azithromycin solution. Doxycycline is dosed at 100 mg bid; essential fatty
      acid is dosed at 1000 mg per day; topical azithromycin is delivered once per day as a 1%
      solution. Treatment with doxycycline is for two months; treatment with essential fatty acids
      is for two months; treatment with topical azithromycin is for one month. Following
      treatment, meibomian glands are again expressed and the lipids measured by spectroscopy
      (FTIR, MALDI-TOF, NMR)for characterization of structure and function. Analysis for presence
      of doxcycline or azithromycin is also performed. Changes in lipid parameters are correlated
      with clinical signs and symptoms of disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammation of eyelid (Clinical; Phase transition temp (Laboratory)</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Character of meibomian gland secretion</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral doxycycline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>essential fatty acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral essential fatty acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical azithromycin daily to the conjunctival culdesac</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
    <description>Oral doxycycline 100mg bid</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>Minocycline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>essential fatty acid</intervention_name>
    <description>Oral essential fatty acid 1000mg per day</description>
    <arm_group_label>essential fatty acid</arm_group_label>
    <other_name>Fish Oil; Flax Seed Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin</intervention_name>
    <description>topical 1% azithromycin daily to eye</description>
    <arm_group_label>azithromycin</arm_group_label>
    <other_name>Azasite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meibomian gland dysfunction

        Exclusion Criteria:

          -  Lid margin scarring; herpetic blepharitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary N Foulks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary N Foulks, MD</last_name>
    <phone>502-852-6150</phone>
    <email>gnfoul01@louisville.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Douglas Borchman, PhD</last_name>
    <phone>502-852-7435</phone>
    <email>borchman@louisville.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kentucky Lions Eye Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary N Foulks, MD</last_name>
      <phone>502-852-6150</phone>
      <email>gnfoul01@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Gary N Foulks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <lastchanged_date>November 23, 2010</lastchanged_date>
  <firstreceived_date>December 1, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Gary N. Foulks, MD</name_title>
    <organization>University of Louisville</organization>
  </responsible_party>
  <keyword>Meibomian gland dysfunction</keyword>
  <keyword>Lid margin disease</keyword>
  <keyword>doxycycline</keyword>
  <keyword>azithromycin</keyword>
  <keyword>essential fatty acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
